567 studies found for:    lenalidomide
Show Display Options
Rank Status Study
1 Recruiting Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide, endoxan, prednisone;   Drug: lenalidomide, endoxan, prednisone
2 Unknown  Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Conditions: Follicular Lymphoma;   Marginal Zone B-Cell Lymphoma;   MALT Lymphoma;   Lymphoma of Mucosa-Associated Lymphoid Tissue;   Lymphoma, Small Lymphocytic;   Waldenstrom Macroglobulinemia;   Mantle-Cell Lymphoma
Interventions: Drug: lenalidomide-low dose dexamethasone plus rituximab;   Drug: Lenalidomide + Rituximab
3 Not yet recruiting Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Lenalidomide;   Drug: Rituximab
4 Recruiting A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subjects ≥ 65 Years of Age
Conditions: Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine-single agent;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination with azacitidine
5 Recruiting Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
Condition: HIV-1 Infection
Interventions: Drug: Part A: lenalidomide dose escalation;   Drug: Part B: lenalidomide;   Drug: Part B: lenalidomide placebo
6 Completed
Has Results
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Condition: Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Interventions: Drug: Lenalidomide;   Drug: Recombinant human erythropoietin
7 Active, not recruiting Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Melphalan, Prednisone, Lenalidomide;   Drug: Cyclophosphamide, Prednisone, Lenalidomide;   Drug: Lenalidomide, dexamethasone
8 Completed
Has Results
Dasatinib in Combination With Revlimid (and Dexamethasone)
Condition: Multiple Myeloma
Interventions: Drug: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg;   Drug: Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg
9 Recruiting Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
10 Completed
Has Results
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Condition: Non-Hodgkins Lymphoma
Intervention: Drug: Lenalidomide
11 Completed Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
12 Recruiting Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
13 Withdrawn Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
Condition: Multiple Myeloma
Interventions: Drug: Vorinostat;   Drug: Lenalidomide;   Drug: Dexamethasone
14 Completed Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
Condition: Cutaneous Lupus Erythematosus (CLE)
Intervention: Drug: lenalidomide (Revlimid®)
15 Recruiting Ipilimumab and Lenalidomide in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Ipilimumab;   Drug: Lenalidomide
16 Active, not recruiting Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Condition: Advanced Cancers
Interventions: Drug: Lenalidomide;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Temsirolimus;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil
17 Recruiting Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomide; Chlorambucil
18 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
19 Completed
Has Results
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide
20 Recruiting Nelfinavir and Lenalidomide/Dexamethasone in Patients With Progressive Multiple Myeloma That Have Failed Lenalidomide-containing Therapy
Condition: Multiple Myeloma
Interventions: Drug: Nelfinavir;   Drug: Lenalidomide;   Drug: Dexamethasone

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years